Targeting macrophages in atherosclerosis using nanocarriers loaded with liver X receptor agonists: A narrow review.

ABSTRACT: Macrophages are involved in the whole process of atherosclerosis, which is characterized by accumulation of lipid and inflammation. Presently, clinically used lipid-lowering drugs cannot completely retard the progress of atherosclerosis. Liver X receptor (LXR) plays a key role in regulation of lipid metabolism and inflammation. Accumulating evidence have demonstrated that synthetic LXR agonists can significantly retard the development of atherosclerosis. However, these agonists induce sever hypertriglyceridemia and liver steatosis. These side effects have greatly limited their potential application for therapy of atherosclerosis. The rapid development of drug delivery system makes it possible to delivery interested drugs to special organs or cells using nanocarriers. Macrophages express va

SUBMITTER: Yang TM 

PROVIDER: S-EPMC10018149 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature